Amgen OncologyAmgen Oncology
  • SCIENCE
    • ALL MODALITIES
    • BiTE® PLATFORM
    • ALL TARGETS
    • MINIMAL RESIDUAL DISEASE
  • PIPELINE
    • MODALITY
    • MALIGNANCY
    • MOLECULE
  • RESOURCES
  • ABOUT

Targets

Explore new and established oncology targets

Targets depicted at cell wall
fms-like tyrosine kinase 3 (FLT3) FAPx4-1BB FAPx4-1BB Complement Component 5 (C5)B-lymphocyte Antigen CD20 IL-2RalphaProteasome Thrombopoietin receptor (TPO-R) Delta-like 3 (DLL3)B Cell Maturation Antigen (BCMA)KRAS mutation G12CPRMT5 Cyclic ADP Ribose hydrolase (CD38)MCL-1, myeloid leukemia cell differentiation protein B-lymphocyte Antigen CD19 prostate-specific membrane antigen (PSMA)KIF18A STEAP1 MUC17CLDN18.2 FGFR2b programmed cell death protein 1 (PD-1) Siglec-3 (CD33)
DLL3
PD-1
PSMA
KRASG12C
BCMA
C5
CD19
CD33
TPO-R
FLT3
IL-2Rα
MCL-1
Proteasome
CD20
MUC17
CLDN18.2
FAP x 4-1BB
STEAP1
IL-21R
FGFR2b
KIF18A
PRMT5